Posts

Showing posts from May, 2021

Risk Based GCP & GLP Monitoring & Audit/GLP Compliance

Image
  GLP Monitoring is an essential activity to ensure the quality of the clinical trials, and also we understand issues at both CRO and sponsor levels. Our well qualified and trained monitors are responsible for ensuring that the study conducted in accordance with the protocol, GCP, GLP, and applicable ethical and regulatory requirements. Our team can fully integrate into the study teams of sponsors or CROs while the conduct of the study, nonetheless monitors are independent of the personnel performing the study. We provide a written report after each site visit. If any issues observed during monitoring, our expert communicates to the CRO and Sponsor as quickly as possible, to mitigate the observed problems. We also suggest and enable prompt corrective actions to mitigate the risk associated with the issues. Such communications and corrective actions shall be documented and provided to the Sponsor. Our well defined SOPs with separate checklists for the initiation visit, routine moni

Pharmacovigilance services | Oxter Research

Image
  Pharmacovigilance services are an area that obviously no pharmaceutical company can afford to make a single mistake with. It can be a time-draining task to decipher all the information from prospective pharmacovigilance companies, costing you valuable working hours. This article therefore gives a simple perspective on the overall operational requirements providers should offer, which could more efficiently streamline the entire process at both pre and post marketing authority levels. By spending ten minutes reading this, you can come away with a basic checklist from which to start researching potential pharmacovigilance solutions providers with more informed insight and direction. Pharmacovigilance solutions providers should be able to offer you comprehensive services during the pre marketing and post marketing phases for each product. This simple 'rule' can avoid having to waste time and potentially substantial amounts of the budget handing over to new pharmacovigilance